STOCK TITAN

DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

DSS (NYSE American: DSS) announced that Impact Biomedical completed its business combination with Zoar Limited and Zoar Labs Limited. DSS had held a majority ownership interest in Impact Biomedical, which became a wholly owned subsidiary of Zoar Limited and was renamed Zoar USA. Each outstanding Impact Biomedical common share converted into the right to receive one Zoar Limited ordinary share.

Impact Biomedical stockholders approved the deal on November 13, 2026. Zoar Limited shares are expected to begin trading on November 18, 2026, on NYSE American under ZOAR. DSS retains its DSS ticker and will provide further details on the deal’s effect on its holdings and financial reporting through SEC filings, as appropriate.

Loading...
Loading translation...
1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Completed business combination moves DSS’s Impact Biomedical investment into a structure whose parent shares are expected to trade publicly.

Negative

  • None.

News Explained

For the fiscal year ended March 31, 2026, Zoar Labs reported approximately $651.7 million in revenue and $77.7 million in net income; these are Zoar Labs figures, not DSS’s consolidated results.

Key Figures

Revenue: approximately $651.7 million Net income: $77.7 million Revenue growth: approximately 17.1% +3 more
Revenue
approximately $651.7 million
Zoar Labs, fiscal year ended March 31, 2026
Net income
$77.7 million
Zoar Labs, fiscal year ended March 31, 2026
Revenue growth
approximately 17.1%
Zoar Labs, year over year for fiscal year ended March 31, 2026
Net income growth
approximately 23.9%
Zoar Labs, year over year for fiscal year ended March 31, 2026
Share exchange ratio
1 ordinary share for each outstanding Impact Biomedical common share
Transaction terms upon completion
Expected trading date
November 18, 2026
Zoar Limited ordinary shares expected to begin trading on NYSE American under ZOAR

Previous Acquisition Reports

2 past events · Latest: Nov 02
Same Type 2 events
  1. Nov 02

    F-4 effectiveness

    24h Move
    +2.4%

    SEC effectiveness advanced the same Zoar combination; closing still awaited stockholder and listing approvals.

  2. Sep 16

    F-4 filing

    24h Move
    +0.3%

    Zoar's Form F-4 filing began the same transaction's SEC review and shareholder-approval process.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

active pharmaceutical ingredients
1 terms
active pharmaceutical ingredients technical
"development, manufacturing, and distribution of active pharmaceutical ingredients (APIs)"
The active pharmaceutical ingredient (API) is the specific chemical or biological substance in a medicine that produces the intended health effect — the ‘engine’ that treats, prevents or diagnoses a condition. Investors watch APIs because they determine a drug’s cost, quality, regulatory approval and patent protection; shortages, manufacturing problems or competition at the API level can directly affect a drug maker’s sales and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WEST HENRIETTA, NY / ACCESS Newswire / November 18, 2026 / DSS, Inc. (NYSE American:DSS) ("DSS" or the "Company") today announced that Impact Biomedical Inc. ("Impact Biomedical"), in which DSS has held a majority ownership interest, has completed its previously announced business combination with Zoar Limited ("Zoar") and Zoar Labs Limited ("Zoar Labs").

The business combination was approved by Impact Biomedical stockholders at a special meeting on November 13, 2026. Following completion, Impact Biomedical became a wholly owned subsidiary of Zoar Limited and was renamed Zoar USA Inc. Each outstanding share of Impact Biomedical common stock was converted into the right to receive one ordinary share of Zoar Limited, pursuant to the transaction terms.

Zoar Limited ordinary shares are expected to begin trading on the NYSE American under the ticker symbol "ZOAR" on November 18, 2026. The completion of the transaction provides a new publicly traded structure for the business and represents an important milestone in DSS's investment history with Impact Biomedical.

Jason Grady, Chief Executive Officer of DSS, commented:

"The successful completion of this transaction is a meaningful milestone for DSS and reflects our continued focus on advancing the potential of our portfolio investments. Through Impact Biomedical, DSS has supported the pursuit of opportunities intended to create long-term shareholder value. The combination with Zoar introduces an established international pharmaceutical operating business to the public markets and provides a new platform for future growth. We believe this development represents an important step in the evolution of our investment and reinforces our commitment to strategic transactions that can strengthen DSS's long-term position and create opportunities for our shareholders."

Zoar is a global pharmaceutical company focused on the development, manufacturing, and distribution of active pharmaceutical ingredients (APIs) and intermediates, as well as contract development and manufacturing services. Zoar Labs reported approximately $651.7 million in revenue and $77.7 million in net income for the fiscal year ended March 31, 2026, representing year-over-year increases of approximately 17.1% and 23.9%, respectively. These figures relate to Zoar Labs and do not represent DSS's consolidated financial results.

The transaction does not change DSS's NYSE American ticker symbol, "DSS." DSS will provide additional information concerning the transaction's impact on its investment holdings and financial reporting, as appropriate, through its SEC filings.

About DSS, Inc.

DSS, Inc. (NYSE American:DSS) is a diversified company with interests across multiple business sectors. For additional information, visit www.dssworld.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements concerning the expected commencement of trading of Zoar Limited ordinary shares, Zoar's business prospects, the potential benefits of the business combination, and potential long-term benefits to DSS and its shareholders. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including market and trading conditions, the ability of Zoar to maintain its listing and execute its business strategy, regulatory and operational risks, and uncertainties relating to DSS's investment and financial reporting. Additional risks are described in DSS's filings with the Securities and Exchange Commission and in filings relating to the business combination. Forward-looking statements speak only as of the date hereof, and DSS undertakes no obligation to update them except as required by law.

Investor Relations

DSS, Inc. | ir@dssworld.com
www.dssworld.com

SOURCE: DSS, Inc.



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Impact Biomedical shareholders receive under the DSS-announced Zoar deal?

Each outstanding Impact Biomedical common share converted into the right to receive one Zoar Limited ordinary share. Impact Biomedical became a wholly owned subsidiary of Zoar Limited and was renamed Zoar USA.

When are Zoar shares expected to begin trading after the DSS-announced deal?

Zoar Limited ordinary shares are expected to begin trading on November 18, 2026, under ZOAR on NYSE American. The transaction does not change the DSS ticker.

What financial results did Zoar Labs report in connection with the DSS-announced combination?

Zoar Labs reported approximately $651.7 million in revenue and $77.7 million in net income for the fiscal year ended March 31, 2026. Revenue and net income rose approximately 17.1% and 23.9% year over year, respectively. These are Zoar Labs figures, not DSS’s consolidated results.

Keep reading